Mature but not immature Fas Ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC

Journal of Immunology

Volumn 170, Issue 11, 2003, Pages 5406-5413

  Hoves, Sabine ^a   Krause, Stefan W ^b   Halbritter, Dagmar ^a   Zhang, Huang Ge ^c   Mountz, John D ^c   Schölmerich, Jürgen ^a   Fleck, Martin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Department of Internal Medicine I   (Germany)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APC; FAS LIGAND; MONOKINE;

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; CELL MATURATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; GENE TRANSFER; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TIME SERIES ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 0038528547     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.11.5406     Document Type: Article

References (55)

1. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
2. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
3. Lutz, M., and G. Schuler. 2002. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23:445.
4. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772.
5. Schwarz, A., S. Grabbe, K. Grosse-Heitmeyer, B. Roters, H. Riemann, T. A. Luger, G. Trinchieri, and T. Schwarz. 1998. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system. J. Immunol. 160:4262.
6. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
7. Oberholzer, A., C. Oberholzer, K. S. Bahjat, R. Ungaro, C. L. Tannahill, M. Murday, F. R. Bahjat, Z. Abouhamze, V. Tsai, D. LaFace, et al. 2002. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J. Immunol. 168:3412.
8. Takayama, T., K. Kaneko, A. E. Morelli, W. Li, H. Tahara, and A. W. Thomson. 2002. Retroviral delivery of transforming growth factor-β1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74:112.
9. Takayama, T., A. E. Morelli, P. D. Robbins, H. Tahara, and A. W. Thomson. 2000. Feasibility of CTLA41g gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther. 7:1265.
10. Krammer, P. H. 2000. CD95's deadly mission in the immune system. Nature 407:789.
11. Igney, F. H., and P. H. Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukocyte Biol. 71:907.
12. Matsue, H., K. Matsue, M. Kusuhara, T. Kumamoto, K. Okumura, H. Yagita, and A. Takashima. 2001. Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 98:3465.
13. + T cells from DOII.10 mice. Eur. J. Immunol. 32:1035.
14. Dulat, H. J., C. von Grumbkow, W. Baars, N. Schröder, K. Wonigeit, and R. Schwinzer. 2001. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur. J. Immunol. 31:2217.
15. Georgantas, R. W., 3rd, K. W. Leong, and J. T. August. 2000. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum. Gene Ther. 11:851.
16. Whartenby, K. A., E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin. 2002. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 100:3147.
17. Fleck, M., H. G. Zhang, E. R. Kern, H. C. Hsu, U. Muller-Ladner, and J. D. Mountz. 2001. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local FasL gene transfer. Arthritis Rheum. 44:964.
18. Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nat. Med. 5:930.
19. Min, W. P., R. Gorczynski, X. Y. Huang, M. Kushida, P. Kim, M. Obataki, J. Lei, R. M. Suri, and M. S. Cattral. 2000. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164:161.
20. Wu, B., J. M. Wu, A. Miagkov, R. N. Adams, H. I. Levitsky, and D. B. Drachman. 2001. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J. Immunol. 166:4773.
21. Zhang, H. G., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz, and T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162:1423.
22. Zhang, H. G., M. Fleck, E. R. Kern, D. Liu, Y. Wang, H. C. Hsu, P. Yang, Z. Wang, D. T. Curiel, T. Zhou, and J. D. Mountz. 2000. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J. Clin. Invest. 105:813.
23. Wolfe, T., C. Asseman, A. Hughes, H. Matsue, A. Takashima, and M. G. Von Herrath. 2002. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J. Immunol. 169:4867.
24. Jenne, L., G. Schuler, and A. Steinkasserer. 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22:102.
25. Shinoura, N., M. Ohashi, Y. Yoshida, A. Asai, T. Kirino, I. Saito, and H. Hamada. 1998. Construction. propagation, and titer estimation of recombinant adenoviruses carrying proapoptotic genes. Hum. Gene Ther. 9:2683.
26. Ammon, C., S. P. Meyer, L. Schwarzfischer, S. W. Krause, R. Andreesen, and M. Kreutz. 2000. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 100:364.
27. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serumfree conditions. Eur. J. Immunol. 27:3135.
28. Zhang, H. G., D. Liu, Y. Heike, P. Yang, Z. Wang, X. Wang, D. T. Curiel, T. Zhou, and J. D. Mountz. 1998. Induction of specific T-cell tolerance by adenovirus-transfected. Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16:1045.
29. Bilbao, G., H. Zhang, J. L. Contreras, T. Zhou, M. Feng, I. Saito, J. D. Mountz, and D. T. Curiel. 1999. Construction of a recombinant adenovirus vector encoding Fas ligand with a CRE/Loxp inducible system. Transplant. Proc. 31:792.
30. Graham, F. L., and L. Prevec. 1995. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:207.
31. Gahn, B., F. Siller-Lopez, A. D. Pirooz, E. Yvon, S. Gottschalk, R. Longnecker, M. K. Brenner, H. E. Heslop, E. Aguilar-Cordova, and C. M. Rooney. 2001. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr viruspositive Hodgkin's lymphoma. Int. J. Cancer 93:706.
32. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
33. + human adherent tumor cells. J. Immunol. Methods 233:179.
34. Zhang, H. G., G. Bilbao, T. Zhou, J. L. Contreras, J. Gomez-Navarro, M. Feng, I. Saito, J. D. Mountz, and D. T. Curiel. 1998. Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J. Virol. 72:2483.
35. Willems, F., Z. Amraoui, N. Vanderheyde, V. Verhasselt, E. Aksoy, C. Scaffidi, M. E. Peter, P. H. Krammer, and M. Goldman. 2000. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 95:3478.
36. Koppi, T. A., T. Tough-Bement, D. M. Lewinsohn, D. H. Lynch, and M. R. Alderson. 1997. CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-defived dendritic cells. Eur. J. Immunol. 27:3161.
37. Rescigno, M., V. Piguet, B. Valzasina, S. Lens, R. Zubler, L. French, V. Kindler, J. Tschopp, and P. Ricciardi-Castagnoli. 2000. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon γ in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192:1661.
38. L. Cancer Immunol. Immunother. 51:139.
39. Kosiewicz, M. M., A. Krishnan, M. T. Worthington, J. A. Matriano, and W. G. Ross. 2002. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo. Eur. J. Immunol. 32:1679.
40. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:621.
41. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151.
42. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:964.
43. Ashany, D., A. Savir, N. Bhardwaj, and K. B. Elkon. 1999. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 163:5303.
44. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625.
45. Meidenbauer, N.,R. Andreesen, and A. Mackensen. 2001. Dendritic cells for specific cancer immunotherapy. Biol. Chem. 382:507.
46. 2, Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 168:1831.
47. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169.
48. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045.
49. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205.
50. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Downregulation of Fas ligand by shedding. Nat. Med. 4:31.
51. Suda, T., M. Tanaka, K. Miwa, and S. Nagata. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 157:3918.
52. Hohlbaum, A. M., S. Moe, and A. Marshak-Rothstein. 2000. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191:1209.
53. Seino, K., K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484.
54. Ottonello, L., G. Tortolina, M. Amelotti, and F. Dallegri. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162:3601.
55. Gregory, M. S., A. C. Repp, A. M. Hohlbaum, R. R. Saff, A. Marshak-Rothstein, and B. R. Ksander. 2002. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169:2727.